2023-11-012024-10-312024-10-31false04649469Messrs M.D Oswald Limited2025-07-2443220falseiso4217:GBPxbrli:pure046494692023-10-31046494692024-10-31046494692023-11-012024-10-31046494692022-10-31046494692023-10-31046494692022-11-012023-10-3104649469bus:SmallEntities2023-11-012024-10-3104649469bus:AuditExempt-NoAccountantsReport2023-11-012024-10-3104649469bus:FullAccounts2023-11-012024-10-3104649469bus:PrivateLimitedCompanyLtd2023-11-012024-10-3104649469core:WithinOneYear2024-10-3104649469core:AfterOneYear2024-10-3104649469core:WithinOneYear2023-10-3104649469core:AfterOneYear2023-10-3104649469core:ShareCapital2024-10-3104649469core:SharePremium2024-10-3104649469core:RevaluationReserve2024-10-3104649469core:OtherReservesSubtotal2024-10-3104649469core:RetainedEarningsAccumulatedLosses2024-10-3104649469core:ShareCapital2023-10-3104649469core:SharePremium2023-10-3104649469core:RevaluationReserve2023-10-3104649469core:OtherReservesSubtotal2023-10-3104649469core:RetainedEarningsAccumulatedLosses2023-10-3104649469core:LandBuildings2024-10-3104649469core:PlantMachinery2024-10-3104649469core:Vehicles2024-10-3104649469core:FurnitureFittings2024-10-3104649469core:OfficeEquipment2024-10-3104649469core:NetGoodwill2024-10-3104649469core:IntangibleAssetsOtherThanGoodwill2024-10-3104649469core:ListedExchangeTraded2024-10-3104649469core:UnlistedNon-exchangeTraded2024-10-3104649469core:LandBuildings2023-10-3104649469core:PlantMachinery2023-10-3104649469core:Vehicles2023-10-3104649469core:FurnitureFittings2023-10-3104649469core:OfficeEquipment2023-10-3104649469core:NetGoodwill2023-10-3104649469core:IntangibleAssetsOtherThanGoodwill2023-10-3104649469core:ListedExchangeTraded2023-10-3104649469core:UnlistedNon-exchangeTraded2023-10-3104649469core:LandBuildings2023-11-012024-10-3104649469core:PlantMachinery2023-11-012024-10-3104649469core:Vehicles2023-11-012024-10-3104649469core:FurnitureFittings2023-11-012024-10-3104649469core:OfficeEquipment2023-11-012024-10-3104649469core:NetGoodwill2023-11-012024-10-3104649469core:IntangibleAssetsOtherThanGoodwill2023-11-012024-10-3104649469core:ListedExchangeTraded2023-11-012024-10-3104649469core:UnlistedNon-exchangeTraded2023-11-012024-10-3104649469core:MoreThanFiveYears2023-11-012024-10-3104649469core:Non-currentFinancialInstruments2024-10-3104649469core:Non-currentFinancialInstruments2023-10-3104649469dpl:CostSales2023-11-012024-10-3104649469dpl:DistributionCosts2023-11-012024-10-3104649469core:LandBuildings2023-11-012024-10-3104649469core:PlantMachinery2023-11-012024-10-3104649469core:Vehicles2023-11-012024-10-3104649469core:FurnitureFittings2023-11-012024-10-3104649469core:OfficeEquipment2023-11-012024-10-3104649469dpl:AdministrativeExpenses2023-11-012024-10-3104649469core:NetGoodwill2023-11-012024-10-3104649469core:IntangibleAssetsOtherThanGoodwill2023-11-012024-10-3104649469dpl:GroupUndertakings2023-11-012024-10-3104649469dpl:ParticipatingInterests2023-11-012024-10-3104649469dpl:GroupUndertakingscore:ListedExchangeTraded2023-11-012024-10-3104649469core:ListedExchangeTraded2023-11-012024-10-3104649469dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-11-012024-10-3104649469core:UnlistedNon-exchangeTraded2023-11-012024-10-3104649469dpl:CostSales2022-11-012023-10-3104649469dpl:DistributionCosts2022-11-012023-10-3104649469core:LandBuildings2022-11-012023-10-3104649469core:PlantMachinery2022-11-012023-10-3104649469core:Vehicles2022-11-012023-10-3104649469core:FurnitureFittings2022-11-012023-10-3104649469core:OfficeEquipment2022-11-012023-10-3104649469dpl:AdministrativeExpenses2022-11-012023-10-3104649469core:NetGoodwill2022-11-012023-10-3104649469core:IntangibleAssetsOtherThanGoodwill2022-11-012023-10-3104649469dpl:GroupUndertakings2022-11-012023-10-3104649469dpl:ParticipatingInterests2022-11-012023-10-3104649469dpl:GroupUndertakingscore:ListedExchangeTraded2022-11-012023-10-3104649469core:ListedExchangeTraded2022-11-012023-10-3104649469dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-11-012023-10-3104649469core:UnlistedNon-exchangeTraded2022-11-012023-10-3104649469core:NetGoodwill2024-10-3104649469core:IntangibleAssetsOtherThanGoodwill2024-10-3104649469core:LandBuildings2024-10-3104649469core:PlantMachinery2024-10-3104649469core:Vehicles2024-10-3104649469core:FurnitureFittings2024-10-3104649469core:OfficeEquipment2024-10-3104649469core:AfterOneYear2024-10-3104649469core:WithinOneYear2024-10-3104649469core:ListedExchangeTraded2024-10-3104649469core:UnlistedNon-exchangeTraded2024-10-3104649469core:ShareCapital2024-10-3104649469core:SharePremium2024-10-3104649469core:RevaluationReserve2024-10-3104649469core:OtherReservesSubtotal2024-10-3104649469core:RetainedEarningsAccumulatedLosses2024-10-3104649469core:NetGoodwill2023-10-3104649469core:IntangibleAssetsOtherThanGoodwill2023-10-3104649469core:LandBuildings2023-10-3104649469core:PlantMachinery2023-10-3104649469core:Vehicles2023-10-3104649469core:FurnitureFittings2023-10-3104649469core:OfficeEquipment2023-10-3104649469core:AfterOneYear2023-10-3104649469core:WithinOneYear2023-10-3104649469core:ListedExchangeTraded2023-10-3104649469core:UnlistedNon-exchangeTraded2023-10-3104649469core:ShareCapital2023-10-3104649469core:SharePremium2023-10-3104649469core:RevaluationReserve2023-10-3104649469core:OtherReservesSubtotal2023-10-3104649469core:RetainedEarningsAccumulatedLosses2023-10-3104649469core:NetGoodwill2022-10-3104649469core:IntangibleAssetsOtherThanGoodwill2022-10-3104649469core:LandBuildings2022-10-3104649469core:PlantMachinery2022-10-3104649469core:Vehicles2022-10-3104649469core:FurnitureFittings2022-10-3104649469core:OfficeEquipment2022-10-3104649469core:AfterOneYear2022-10-3104649469core:WithinOneYear2022-10-3104649469core:ListedExchangeTraded2022-10-3104649469core:UnlistedNon-exchangeTraded2022-10-3104649469core:ShareCapital2022-10-3104649469core:SharePremium2022-10-3104649469core:RevaluationReserve2022-10-3104649469core:OtherReservesSubtotal2022-10-3104649469core:RetainedEarningsAccumulatedLosses2022-10-3104649469core:AfterOneYear2023-11-012024-10-3104649469core:WithinOneYear2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:CostValuation2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-11-012024-10-3104649469core:Non-currentFinancialInstrumentscore:CostValuation2024-10-3104649469core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-10-3104649469core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-10-3104649469core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-10-3104649469core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-10-3104649469core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-10-3104649469core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-10-3104649469core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-10-3104649469core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-10-3104649469core:Non-currentFinancialInstrumentscore:CostValuation2023-10-3104649469core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-10-3104649469core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-10-3104649469core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-10-3104649469core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-10-3104649469core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-10-3104649469core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-10-3104649469core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-10-3104649469core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-10-3104649469bus:Director12023-11-012024-10-3104649469bus:Director22023-11-012024-10-3104649469core:FurnitureFittingsToolsEquipment2023-10-3104649469core:FurnitureFittingsToolsEquipment2024-10-3104649469core:FurnitureFittingsToolsEquipment2023-11-012024-10-31

Messrs M.D Oswald Limited

Registered Number
04649469
(England and Wales)

Unaudited Financial Statements for the Year ended
31 October 2024

Messrs M.D Oswald Limited
Company Information
for the year from 1 November 2023 to 31 October 2024

Directors

Sharon Oswald
Stuart Michael Oswald

Registered Address

9 Trinity Way
Keswick
CA12 4HZ

Registered Number

04649469 (England and Wales)
Messrs M.D Oswald Limited
Statement of Financial Position
31 October 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets49,33912,469
9,33912,469
Current assets
Stocks65001,500
Debtors717,6329,882
Cash at bank and on hand975647
19,10712,029
Creditors amounts falling due within one year8(26,351)(21,283)
Net current assets (liabilities)(7,244)(9,254)
Total assets less current liabilities2,0953,215
Provisions for liabilities11(1,774)(2,302)
Net assets321913
Capital and reserves
Called up share capital490490
Profit and loss account(169)423
Shareholders' funds321913
The financial statements were approved and authorised for issue by the Board of Directors on 24 July 2025, and are signed on its behalf by:
Sharon Oswald
Director
Stuart Michael Oswald
Director

Registered Company No. 04649469
Messrs M.D Oswald Limited
Notes to the Financial Statements
for the year ended 31 October 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Judgements and key sources of estimation uncertainty
Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. There are no key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)Straight line (years)
Plant and machinery153
Fixtures and fittings15-
Vehicles25-
Finance leases and hire purchase contracts
Assets held under finance leases and hire purchase contracts which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company are recognised in the statement of financial position as assets and liabilities at the lower of the fair value of the assets and the present value of the minimum lease payments, which is determined at the inception of the lease term. Any initial direct costs of the lease are added to the amount recognised as an asset. Lease payments are apportioned between the finance charges and reduction of the outstanding lease liability using the effective interest method. Finance charges are allocated to each period so as to produce a constant rate of interest on the remaining balance of the liability. Operating lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Government grants or assistance
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received. A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.
2.Average number of employees

20242023
Average number of employees during the year23
3.Deferred tax
Increases in the UK Corporation tax rate from 19% to 25% (19% effective from 1 April 2017, and 25% effective from 1 April 2023) have been substantively enacted. This will impact the company's future tax charge accordingly. The value of the deferred tax assets at the balance sheet date has been calculated using the applicable rate when the asset is expected to be realised.
4.Tangible fixed assets

Plant & machinery

Vehicles

Fixtures & fittings

Total

££££
Cost or valuation
At 01 November 239,54427,5402,76939,853
At 31 October 249,54427,5402,76939,853
Depreciation and impairment
At 01 November 238,80515,9222,65727,384
Charge for year2082,905173,130
At 31 October 249,01318,8272,67430,514
Net book value
At 31 October 245318,713959,339
At 31 October 2373911,61811212,469
5.Impairment of tangible fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
6.Stocks

2024

2023

££
Work in progress5001,500
Total5001,500
7.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables1,575-
Other debtors16,0579,882
Total17,6329,882
8.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables17,64614,880
Taxation and social security6,8054,348
Other creditors-55
Accrued liabilities and deferred income1,9002,000
Total26,35121,283
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
9.Creditors: amounts due after one year
10.Obligations under finance leases
11.Provisions for liabilities
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset.

2024

2023

££
Net deferred tax liability (asset)1,7742,302
Total1,7742,302
12.Directors advances, credits and guarantees
Included within other debtors falling due within one year is £15,920 (2023 - £9,606) being the amount owed by the director. Net amounts advanced during the year were £6,314. These amounts were both repaid within nine months of the financial year. The loans where charged the official rate of interest were applicable and were repayable on demand.